DXCM: DexCom, Inc. - Summary | Jitta

DexCom, Inc.

NASDAQ:DXCM

Price
$118.24
Loss Chance
45.3%
6.25JITTA SCORE
> 1,000%Over Jitta Line
Jitta Ranking
87 / 1,142
956 / 5,003
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (71)
Recent Business Performance (63)
Financial Strength (77)
Return to Shareholders (51)
Competitive Advantage (77)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing
Revenue and EarningRevenue decline from 2019-2022
Operating MarginInconsistent
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
6.25
> 1,000%
2.03
336.26%
Health Care Equipment
6.23
22.23%
4.76
21.25%
6.29
15.60%
COMPANY DESCRIPTION
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.